Drug Profile
Research programme: hepatitis B vaccine - NasVax/SciGen
Latest Information Update: 05 Jul 2011
Price :
$50
*
At a glance
- Originator NasVax; SciGen
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hepatitis B
Most Recent Events
- 11 Dec 2007 Preclinical trials in Hepatitis B prevention in Israel (Intranasal)
- 11 Dec 2007 Preclinical trials in Hepatitis B prevention in Singapore (Intranasal)